In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vascular Therapies, Inc.

http://www.vasculartx.com

Latest From Vascular Therapies, Inc.

Promethera names chair of board

Promethera Biosciences, a Belgian biotechnology company developing a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has named Dr John Tchelingerian chair of its board of directors. Dr Tchelingerian is a serial entrepreneur and a private investor. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos.

Companies

Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

BioPharmaceutical Japan

Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

BioPharmaceutical Japan

Demand for non-clinical development support drives L2D expansion

An increase in demand from small- and medium-sized drug development companies for non-clinical development support has led to one young CRO, Leads to Development (L2D), opening new two new offices alongside its Paris, France base.

France
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register